Combination of CAR-DC Vaccine and PD-1 Antibody in Local Advanced/Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors to
determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC
vaccine loaded with KRAS mutant peptide (KRAS-EphA-2-CAR-DC) in combination with PD-1
antibody. It aims to: assess the safety and antitumor effects of KRAS-EphA-2-CAR-DC vaccine;
detect T cell response against KRAS mutant peptide and tumor neoepitopes after the treatment
with KRAS-EphA-2-CAR-DC vaccine and PD-1 antibody.